Danisco US Inc.

Other

Mats Sandgren

Frits Goedegebuur

Andrew Shaw

Colin Mitchinson

Anthony G Day

Peter Gualfetti

Jerry Stahlberg

Richard Ray Bott

Bradley R Kelemen

Thijs Kaper

Slavko Kralj

Igor Nikolaev

Sander Van Stigt Thans

Paulien Neefe

Gudrun Vogtentanz

Johannes Franciscus Thomas Van Lieshout

David Aaron Estell

Benjamin S Bower

Wolfgang Aehle

Louise Wallace

Ronaldus Wilhelmus Hommes

Jonathan Caspi

Paulien Neefe-Kruithof

Ronaldus W J Hommes

Torleif Härd

Maria Foukaraki

Ronaldus Wilhelmus Joannes Hommes

Paulien Kruithof

Benjamin Schmuck

Wilhelmus Antonious Hendricus Van Der Kley

Johan Van Lieshout

The present embodiments relate to antibody binding nanofibrils obtainable by co-fibrillation of carrier proteins and carrier-Z fusion proteins at a molar ratio selected within an interval of from 1:0.20 to 1:0.90. The antibody binding nanofibrils have extremely high antibody binding capacity and can thereby be used in various applications, such as antibody purification, and detection of biomarkers in point of care or laboratory diagnosis applications. (FIG.).

Antibody binding nanofibrils

Disclosed are a number of homologs and variants ofCe17A (formerlycellobiohydrolase I or CBH1), nucleic acids encoding the same and methods for producing the same. The homologs and variant cellulases have the amino acid sequence of a glycosyl hydrolase of family 7A wherein one or more amino acid residues are substituted and/or deleted.

Variants of cellobiohydrolases

Described herein are variants ofCBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.

[object Object]

The present disclosure relates to cellulase variants. In particular the present disclosure relates to cellulase variants having improved expression, activity and/or stability. Also described are nucleic acids encoding the cellulase variants, compositions comprising the cellulase variants, and methods of use thereof.

Cellulase variants with improved expression, activity and stability, and use thereof

The present disclosure is generally directed to enzymes and in particular beta-glucosidase variants. Also described are nucleic acids encoding beta-glucosidase variants, compositions comprising beta-glucosidase variants, methods of using beta-glucosidase variants, and methods of identifying additional useful beta-glucosidase variants.

Beta-glucosidase I variants with improved properties

Growing community of inventors

Uppsala, Sweden

Mats Sandgren